Cognitive Impairment in Parkinson's Disease: What We Know so Far

被引:5
|
作者
Painous, Celia [1 ]
Marti, Maria J. [1 ]
机构
[1] Univ Barcelona, Parkinson & Movement Disorders Unit, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Neurol Serv,Hosp Clin Univ,Ctr Invest Biomed Red, Barcelona, Catalonia, Spain
来源
RESEARCH AND REVIEWS IN PARKINSONISM | 2020年 / 10卷
关键词
Parkinson; dementia; mild cognitive impairment; review; biomarker; diagnosis; treatment; WHITE-MATTER HYPERINTENSITIES; NONINVASIVE BRAIN-STIMULATION; CLINICAL DIAGNOSTIC-CRITERIA; DRUG-INDUCED PSYCHOSIS; FLUID ALPHA-SYNUCLEIN; LEWY BODIES; ALZHEIMERS-DISEASE; DOUBLE-BLIND; A-BETA; DOPAMINE DYSFUNCTION;
D O I
10.2147/JPRLS.S263041
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
One of the most impactful non-motor manifestations of Parkinson's disease (PD) is cognitive impairment. Cognitive decline in PD exists as a continuum, with symptoms ranging from normal cognition to mild cognitive impairment (MCI) and finally dementia (PDD). MCI is clinically heterogeneous and its progression varies with cases reverting to normal cognition. On the contrary, when dementia occurs, the decline is usually rapid and stereotyped. The combination of Lewy and Alzheimer's disease pathology is the most robust pathological correlate of PDD. There are no approved drugs for PD-MCI and the benefit from the only approved symptomatic treatment for PDD is modest. This review aims to present the aspects in which greater evidence exists and summarize the epidemiology, pathogenesis, clinical features, diagnostic approach, and treatment of cognitive dysfunction and dementia in PD.
引用
收藏
页码:7 / 17
页数:11
相关论文
共 50 条
  • [31] Treating Alzheimer's disease with cholinesterase inhibitors: What have we learned so far?
    Feldman, H
    INTERNATIONAL PSYCHOGERIATRICS, 2002, 14 : 3 - 5
  • [32] Parkinson's Disease and Cognitive Impairment
    Yang, Yang
    Tang, Bei-sha
    Guo, Ji-feng
    PARKINSONS DISEASE, 2016, 2016
  • [33] Magnetic resonance imaging: A biomarker for cognitive impairment in Parkinson's disease?
    Duncan, Gordon W.
    Firbank, Michael J.
    O'Brien, John T.
    Burn, David J.
    MOVEMENT DISORDERS, 2013, 28 (04) : 425 - 438
  • [34] Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
    Melzer, Tracy R.
    Stark, Megan R.
    Keenan, Ross J.
    Myall, Daniel J.
    MacAskill, Michael R.
    Pitcher, Toni L.
    Livingston, Leslie
    Grenfell, Sophie
    Horne, Kyla-Louise
    Young, Bob N.
    Pascoe, Maddie J.
    Almuqbel, Mustafa M.
    Wang, Jian
    Marsh, Steven H.
    Miller, David H.
    Dalrymple-Alford, John C.
    Anderson, Tim J.
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [35] White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease
    Mak, Elijah
    Dwyer, Michael G.
    Ramasamy, Deepa P.
    Au, Wing Lok
    Tan, Louis C. S.
    Zivadinov, Robert
    Kandiah, Nagaendran
    JOURNAL OF NEUROIMAGING, 2015, 25 (05) : 754 - 760
  • [36] Mild cognitive impairment exists in Parkinson's disease
    Rektorova, Irena
    JOURNAL OF NEURAL TRANSMISSION, 2011, 118 (08) : 1179 - 1183
  • [37] Visual Hallucinations and Cognitive Impairment in Parkinson's Disease
    Park, Hee Kyung
    Kim, Jae Seung
    Im, Ki Chun
    Kim, Mi Jung
    Lee, Jae-Hong
    Lee, Myoung C.
    Kim, Juhan
    Chung, Sun Ju
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2013, 40 (05) : 657 - 662
  • [38] The Treatment of Cognitive Impairment Associated with Parkinson's Disease
    Burn, David J.
    BRAIN PATHOLOGY, 2010, 20 (03) : 672 - 678
  • [39] Fire effects on anurans: What we know so far?
    dos Anjos, Amanda Gomes
    Sole, Mirco
    Benchimol, Maira
    FOREST ECOLOGY AND MANAGEMENT, 2021, 495
  • [40] Fetal nephrolithiasis: What do we know so far?
    Petrovic, Oleg
    Raspor, Sanja Flajsman
    Krajina, Robert
    Ivandic, Jelena
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2024, 165 (01) : 385 - 387